New research shows that young breast cancer patients with high-risk genes may be able to prevent their cancer from returning ...
It’s been long known that women with BRCA1 and BRCA2 gene mutations are at higher risk for breast and ovarian cancer. More ...
The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients ...
Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk ...
First-in-human results for three investigational inhibitors show anti-tumor activity without unmanageable effects on blood glucose.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback